Clinical data
ATC code None
Legal status
Legal status
  • US: Investigational new drug
CAS Number 1293281-49-8 YesY
PubChem (CID) 67116280
Chemical and physical data
Formula C21H22FN7O
Molar mass 407.443 g/mol
3D model (Jmol) Interactive image

MIN-202 (also known as JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).[1][2][3] As of December 2015, it is in phase II clinical trials for both insomnia and MDD.[2][4][5]

See also


  1. Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst. 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
  2. 1 2 Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.
  3. Cristoph Boss; Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012.
  4. "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
  5. Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.

Further reading

This article is issued from Wikipedia - version of the 10/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.